HLB Therapeutics Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 170.78 million compared to KRW 384.76 million a year ago. Net loss was KRW 1,001.53 million compared to KRW 3,030.69 million a year ago. Basic loss per share from continuing operations was KRW 15.5362 compared to KRW 45.5927 a year ago. Diluted loss per share from continuing operations was KRW 15.5072 compared to KRW 45.5927 a year ago. Basic loss per share was KRW 13.7971 compared to KRW 94.3768 a year ago. Diluted loss per share was KRW 13.7681.
For the nine months, sales was KRW 185.78 million compared to KRW 407.86 million a year ago. Net income was KRW 1,875.74 million compared to net loss of KRW 4,995.76 million a year ago. Basic earnings per share from continuing operations was KRW 26.715 compared to basic loss per share from continuing operations of KRW 75.157 a year ago. Diluted earnings per share from continuing operations was KRW 26.657 compared to diluted loss per share from continuing operations of KRW 75.157 a year ago. Basic earnings per share was KRW 25.4589 compared to basic loss per share of KRW 155.5749 a year ago. Diluted earnings per share was KRW 25.401.